title: Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case-Control Study.
abstract: BACKGROUND
  To evaluate the risk of breast cancer associated with long-term use of antihypertensive agents (AHs) in Taiwanese women with hypertension.
  
  
  METHODS
  A search of the Taiwan National Health Insurance Research Database identified 330,699 patients with hypertension who were treated with antihypertensive drugs between January 1, 1998 and December 31, 2011. Logistic regression models were used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) between the use of AHs and breast cancer risk, adjusted for other types of antihypertensive drugs, statins and co-morbidities.
  
  
  RESULTS
  Among the AHs used to treat the hypertensive women enrolled in our study, our analysis revealed that those treated with one specific particular class of beta-blockers (beta-1 selective beta-blockers) had an increased risk for breast cancer. We also found that the ever-use of calcium channel blockers (CCBs; i.e. for 13 years) was associated with breast cancer in an adjusted model (OR 1.09; 95% CI 1.03-1.16). However, the use of nonselective beta-blockers, selective and nonselective alpha-blockers, angiotensin-converting enzyme inhibitors and angiotensin II antagonists were not associated with breast cancer risk.
  
  
  CONCLUSIONS
  Based on the results of our analysis, long-term use of CCBs or beta-1 selective beta-blockers are likely to be associated with the risk of breast cancer. Further large comprehensive population-based studies to support our findings are required for confirmation of this conclusion.
authors: Department of Radiation Oncology, China Medical University-An Nan Hospital, Tainan, Taiwan.
authors: Henry W C
authors: HW
authors: Leung
authors: Li-Ling
authors: LL
authors: Hung
authors: Agnes L F
authors: AL
authors: Chan
authors: Chih-Hsin
authors: CH
authors: Mou
references: Cancer Causes Control. 2013 Feb;24(2):365-71
references: 23224328
references: Lancet Oncol. 2011 Jan;12(1):65-82
references: 21123111
references: Pharm Biol. 2014 Nov;52(11):1374-81
references: 25026350
references: Int J Oncol. 2002 Jul;21(1):153-7
references: 12063562
references: Cancer Res. 2010 Sep 15;70(18):7042-52
references: 20823155
references: Lancet Oncol. 2010 Jul;11(7):627-36
references: 20542468
references: J Clin Oncol. 2011 Jul 1;29(19):2645-52
references: 21632501
references: J Chronic Dis. 1987;40(5):373-83
references: 3558716
references: JAMA Intern Med. 2013 Sep 23;173(17):1629-37
references: 23921840
references: Int J Cancer. 2004 Nov 1;112(2):231-8
references: 15352035
references: Breast Cancer Res Treat. 2011 Dec;130(3):747-58
references: 21234673
references: Circulation. 2011 Apr 26;123(16):1729-36
references: 21482967
references: Br J Clin Pharmacol. 2011 Jul;72 (1):157-61
references: 21453301
references: Nat Rev Clin Oncol. 2011 Aug 02;8(9):511-2
references: 21808268
references: Breast Cancer Res Treat. 2000 Mar;60(2):153-66
references: 10845278
references: Oncotarget. 2010 Nov;1(7):628-38
references: 21317458
references: Breast Cancer Res Treat. 2003 Jul;80(1):63-70
references: 12889599
references: J Clin Oncol. 2011 Jul 1;29(19):2612-6
references: 21632500
references: Breast Cancer Res Treat. 2011 Sep;129(2):549-56
references: 21479924
references: Oncogene. 2007 May 31;26(26):3777-88
references: 17260025
references: Int J Epidemiol. 2013 Dec;42(6):1852-61
references: 24536096
references: Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):410-9
references: 23426547
references: J Hypertens. 2011 Apr;29(4):623-35
references: 21358417
references: Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):711-8
references: 24829113